These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 15221994)

  • 1. Early prostate-specific antigen (PSA) kinetics following prostate carcinoma radiotherapy: prognostic value of a time-and-PSA threshold model.
    Cavanaugh SX; Kupelian PA; Fuller CD; Reddy C; Bradshaw P; Pollock BH; Fuss M
    Cancer; 2004 Jul; 101(1):96-105. PubMed ID: 15221994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
    Miller N; Smolkin ME; Bissonette E; Theodorescu D
    Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.
    Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL
    Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Nadir PSA and kinetics of PSA decline between the 3rd and 6th month after external beam radiotherapy for T1 T2 Nx M0 localized prostate cancer: value of the prediction of the risk of biological progression].
    Almeras C; Zerbib M; Eschwege F; Debré B
    Prog Urol; 2002 Apr; 12(2):219-25. PubMed ID: 12108335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of PSA nadir and the time to nadir in the disease-free period in localized prostatic carcinoma treated with radical radiation].
    Cambeiro M; Azinovic I; Villafranca E; Moreno-Jiménez M; Cañón R; Aristu JJ; Beltrán C; López-Picazo JM; Fernández J; Rebollo J
    Rev Med Univ Navarra; 2001; 45(1):20-8. PubMed ID: 11488204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling time.
    Ciezki JP; Reddy CA; Garcia J; Angermeier K; Ulchaker J; Mahadevan A; Chehade N; Altman A; Klein EA
    Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):512-7. PubMed ID: 16213667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Biochemical monitoring of prostate cancer treated exclusively by radiotherapy: prognostic value of pretreatment PSA, PSA nadir and PSA half-life].
    Chautard D; Cellier P; Dalifard I; Pabot du Chatelard P; Chaussis F; Vielle B; Soret JY; Passagot J; Courte C; Daver A
    Prog Urol; 2002 Jun; 12(3):421-8. PubMed ID: 12189749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. External beam radiotherapy and hyperthermia in the treatment of patients with locally advanced prostate carcinoma.
    Algan O; Fosmire H; Hynynen K; Dalkin B; Cui H; Drach G; Stea B; Cassady JR
    Cancer; 2000 Jul; 89(2):399-403. PubMed ID: 10918172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure.
    Ray ME; Levy LB; Horwitz EM; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Zelefsky MJ; Zietman AL; Kuban DA
    Urology; 2006 Dec; 68(6):1257-62. PubMed ID: 17141830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality.
    Chung CS; Chen MH; Cullen J; McLeod D; Carroll P; D'Amico AV
    Urology; 2008 Jan; 71(1):136-40. PubMed ID: 18242382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postradiotherapy 2-year prostate-specific antigen nadir as a predictor of long-term prostate cancer mortality.
    Zelefsky MJ; Shi W; Yamada Y; Kollmeier MA; Cox B; Park J; Seshan VE
    Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1350-6. PubMed ID: 19515504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate-specific antigen kinetics after brachytherapy or external beam radiotherapy and neoadjuvant hormonal therapy.
    Pinkawa M; Fischedick K; Piroth MD; Gagel B; Borchers H; Jakse G; Eble MJ
    Urology; 2007 Jan; 69(1):129-33. PubMed ID: 17270634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of prostate-specific antigen bounce after I(125) permanent seed implant for localised prostate cancer.
    Mitchell DM; Swindell R; Elliott T; Wylie JP; Taylor CM; Logue JP
    Radiother Oncol; 2008 Jul; 88(1):102-7. PubMed ID: 18453022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer.
    Wong WW; Schild SE; Vora SA; Halyard MY
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):24-9. PubMed ID: 15337536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postoperative radiotherapy for localized prostate cancer: clinical significance of nadir prostate-specific antigen value within 12 months.
    Ogawa K; Nakamura K; Sasaki T; Onishi H; Koizumi M; Araya M; Mukumoto N; Mitsumori M; Teshima T;
    Anticancer Res; 2009 Nov; 29(11):4605-13. PubMed ID: 20032410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time and PSA threshold model prognosticates long-term overall and disease-specific survival in prostate cancer patients as early as 3 months after external beam radiation therapy.
    Cavanaugh SX; Fuller CD; Kupelian PA; Reddy C; Bradshaw P; Pollock BH; Fuss M
    Prostate Cancer Prostatic Dis; 2005; 8(4):353-8. PubMed ID: 16158079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
    Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PSA bouncing after short term androgen deprivation and 3D-conformal radiotherapy for localized prostate adenocarcinoma and the relationship with the kinetics of testosterone.
    Akyol F; Ozyigit G; Selek U; Karabulut E
    Eur Urol; 2005 Jul; 48(1):40-5. PubMed ID: 15967250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. External beam radiotherapy for clinically localized hormone-refractory prostate cancer: clinical significance of Nadir prostate-specific antigen value within 12 months.
    Ogawa K; Nakamura K; Sasaki T; Onishi H; Koizumi M; Shioyama Y; Araya M; Mukumoto N; Mitsumori M; Teshima T;
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(3):759-65. PubMed ID: 19327908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate specific antigen nadir achieved by men apparently cured of prostate cancer by radiotherapy.
    Critz FA; Levinson AK; Williams WH; Holladay CT; Griffin VD; Holladay DA
    J Urol; 1999 Apr; 161(4):1199-203; discussion 1203-5. PubMed ID: 10081869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.